• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Helix Holdings Ii Llc

    2/10/25 5:07:46 PM ET
    $HLXB
    Get the next $HLXB alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Helix Holdings II LLC

    (Last) (First) (Middle)
    C/O HELIX ACQUISITION CORP. II
    200 CLARENDON ST, 52ND FLOOR

    (Street)
    BOSTON MA 02116

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Helix Acquisition Corp. II [ HLXB ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    02/08/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Class B Ordinary Shares (1) 02/08/2025 J(2) 30,000 (1) (1) Class A Ordinary Shares 30,000 $0 4,480,000 D(3)
    Explanation of Responses:
    1. . The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination on a one-for-one basis (unless otherwise provided in Issuer's initial business combination agreement), subject to adjustment for share subdivisions, share consolidations, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-276591) and have no expiration date.
    2. On February 8, 2025, the Reporting Person transferred 30,000 Class B Ordinary Shares owned by it to Albert A. Holman, III in connection with his appointment as a director of the Issuer.
    3. The Reporting Person is the record holder of such securities. Cormorant Private Healthcare Fund III, LP, a Delaware limited partnership, Cormorant Private Healthcare Fund V, LP, a Delaware limited partnership, and Cormorant Global Healthcare Master Fund, LP, a Cayman Islands limited partnership, are the members of Helix Holdings II LLC. Bihua Chen is the manager of the Reporting Person and is the managing member of each of the three members of the Reporting Person and has voting and investment discretion with respect to the ordinary shares held of record by Reporting Person. Ms. Chen disclaims any beneficial ownership of the securities held by the Reporting Person other than to the extent of any pecuniary interest she may have therein, directly or indirectly.
    Remarks:
    Ms. Chen serves on the Board of Directors of the Issuer. Helix Holdings II LLC may be deemed to be a director by deputization as a result of the service of Ms. Chen.
    /s/ Bihua Chen, as manager of Helix Holdings II LLC 02/10/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HLXB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HLXB

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HLXB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics Announce Effectiveness of Registration Statement for Proposed Business Combination

      Extraordinary General Meeting of Helix Shareholders Scheduled for August 4, 2025 SOUTH SAN FRANCISCO & BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Helix Acquisition Corp. II ("Helix") (NASDAQ:HLXB), a special purpose acquisition company ("SPAC") sponsored by Cormorant Asset Management, and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics) ("BBOT"), a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies, today announced that the registration statement on Form S-4 (File No. 333-288222) (as amended, the "Registration Statement"), filed by Helix and BBOT, relating to the previously-announced b

      7/11/25 7:43:00 AM ET
      $BBIO
      $HLXB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines

      Total proceeds, assuming no redemptions, are expected to be $450 million, combining funds held in the Helix Acquisition Corp. II trust account and a private investment in public equity (PIPE) financing Leading institutional investors commit approximately $260 million through a PIPE led by Cormorant Asset Management Business combination is expected to be completed in the third quarter of 2025 The combined entity will be named BridgeBio Oncology Therapeutics (BBOT) and will be advancing a next-generation pipeline of therapies for patients with RAS and PI3Kα malignancies TheRas, Inc. d/b/a BridgeBio Oncology Therapeutics ("BBOT"), a clinical-stage biopharmaceutical company advanci

      2/28/25 7:49:00 AM ET
      $BBIO
      $HLXB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HLXB
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Helix Acquisition Corp. II

      SCHEDULE 13G - Helix Acquisition Corp. II (0001869105) (Subject)

      7/24/25 9:05:28 PM ET
      $HLXB
    • SEC Form 424B3 filed by Helix Acquisition Corp. II

      424B3 - Helix Acquisition Corp. II (0001869105) (Filer)

      7/21/25 9:05:22 PM ET
      $HLXB
    • SEC Form 425 filed by Helix Acquisition Corp. II

      425 - Helix Acquisition Corp. II (0001869105) (Subject)

      7/21/25 8:10:22 AM ET
      $HLXB

    $HLXB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Holman Albert A Iii

      3 - Helix Acquisition Corp. II (0001869105) (Issuer)

      2/11/25 5:16:28 PM ET
      $HLXB
    • SEC Form 4 filed by Director Helix Holdings Ii Llc

      4 - Helix Acquisition Corp. II (0001869105) (Issuer)

      2/10/25 5:07:46 PM ET
      $HLXB
    • SEC Form 4 filed by CEO and Chairperson Chen Bihua

      4 - Helix Acquisition Corp. II (0001869105) (Issuer)

      2/10/25 5:06:42 PM ET
      $HLXB

    $HLXB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Helix Acquisition Corp. II

      SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)

      11/14/24 1:22:40 PM ET
      $HLXB
    • SEC Form SC 13G filed by Helix Acquisition Corp. II

      SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)

      2/23/24 4:30:20 PM ET
      $HLXB
    • SEC Form SC 13G filed by Helix Acquisition Corp. II

      SC 13G - Helix Acquisition Corp. II (0001869105) (Subject)

      2/23/24 4:01:43 PM ET
      $HLXB